The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), has begun a Phase I trial evaluating three experimental messenger RNA (mRNA) HIV vaccines. These vaccines are based on the same technology as the COVID-19 vaccines developed by Pfizer/BioNTech and Moderna.
The HVTN 302 trial (NCT05217641), sponsored by NIAID, is being conducted by NIAID-funded HIV Vaccine Trials Network (HVTN), based at Fred Hutchinson Cancer Research Center in Seattle, US.